Richard Kollender

Richard has more than 30 years of financial, operational and business development experience in the healthcare industry. Richard is currently Chief Financial Officer and Chief Business Officer of Reaction Biology Corporation, a provider of drug discovery services. Richard also serves as Managing Partner of Quaker Partners, a healthcare-focused venture capital and growth equity firm with $700 million under management, where he has led investments and served as an active Chairman or board member of more than a dozen private and publicly traded companies, including Rapid Micro Biosystems.

Prior to joining Reaction Biology, Richard was President and Chief Financial Officer of Strongbridge Biopharma (NASDAQ:SBBP), a commercial stage rare disease pharmaceutical company which was acquired by Xeris Pharmaceuticals in late 2021. Previously, he held positions in sales, marketing, global business development, and venture capital at GlaxoSmithKline (GSK) and its corporate venture arm, S.R. One.

Richard began his career as a Certified Public Accountant initially with KPMG, and his practice had a significant emphasis on the healthcare and emerging businesses sectors.

Richard is an adjunct faculty member at Lehigh University and Chairman of the board of directors for Restorative Therapies. Richard holds an MBA and a certificate degree in the graduate program in health administration and policy from the University of Chicago and a BA in Business Administration and Accounting from Franklin and Marshall College.